
## **Trustees’ Annual Report for the period** 

## **From  25/7/2019 Period start date   To   24/7/2020              Period end date** 

**Charity name:** ASSOCIATION FOR THE GLOBAL ADVANCEMENT OF ENT SURGERY AND HEAD AND NECK CANCER RESEARCH 

## **Charity registration number:** 1165453 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|The advancement of health and relief of<br>sickness in the field of ear, nose and<br>throat/head and neck surgery and head<br>and neck disorders across the world in<br>particular but not exclusively by:<br>· Supporting the provision of awareness<br>and screening programmes<br>· Supporting cancer research by the<br>provision of grants<br>(AGA-ENT Charity Governing document -<br>version 1.1-21/1/2016)|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or<br>services identified in the<br>accounts.|Para 1.17 and<br>1.19|· Supporting the provision of awareness<br>and screening programmes<br>· Supporting cancer research by the<br>provision of grants|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|Yes, the trustees have had regard.|



## **Additional information (optional)** 

## You may choose to include further statements where relevant about: 

SORP reference N/A Para 1.38 Policy on grant making N/A Para 1.38 Policy on social investment including program related investment 



|Contribution made by<br>volunteers|Para 1.38|Minor contributions, e.g. help with website<br>and design of logo|
|---|---|---|
|Other||N/A|



## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|After our BICRAA app (www.bicraa.org)<br>has been successfully tested in India<br>(n=1049), showing that around 30% chew<br>betel nut (we would like to thank Prof.<br>Kelkar and Dr. Pethe from the Deenanath<br>Mangeshkar Hospital, Pune, for their<br>invaluable support), the app has continued<br>to help raise the awareness of the risks of<br>betel nut chewing. We have now been<br>working on a global study to extend these<br>efforts in India and other countries.<br>With regard to our work in Indonesia, we<br>have continued to closely work with our<br>partners at the Dr. Sardjito Hospital/Gadjah<br>Mada University in Yogyakarta, Indonesia,<br>and affiliated district general hospitals in<br>collaboration with Prof. Bing Tan to support<br>the local Nasopharyngeal Cancer (NPC)<br>awareness and early detection programme<br>and to support research and publications of<br>results. The company Storz has continued<br>to support our programme and in 2019 we<br>were able to award four fellowship grants to<br>young surgeons, sponsored by a donation<br>by the company Storz, allowing them travel<br>to low and middle income countries and<br>helping with the local charitable work.|
|**Additional information (optional)**<br>You may choose to include further statements||where relevant about:|
|Achievements against<br>objectives set|Para 1.41|As above. Taking the above work into<br>account AGA-ENT has made contributions<br>to the advancement of health and relief of<br>sickness in the field of ear, nose and<br>throat/head and neck surgery and head<br>and neck disorders in low and middle<br>income countries.|
|Performance of fundraising<br>activities against objectives<br>set|Para 1.41|Good progress. Substantive funding will be<br>sought once the preliminary data are<br>published.|
|Investment performance<br>against objectives|Para 1.41|N/A|





NIA
Other

## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|24/7/2020|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|Year on year the charity hopes to increase<br>the reserves to in line with 2 years possible<br>commitments|
|Amount of reserves held|Para 1.22|£1000|
|Reasons for holding zero<br>reserves|Para 1.22|N/A|
|Details of fund materially in<br>deficit|Para 1.24|N/A|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|N/A|



|**Additional information (optional)**<br>You may choose to include further statements|**Additional information (optional)**<br>You may choose to include further statements|where relevant about:|
|---|---|---|
|The charity’s principal<br>sources of funds (including<br>any fundraising)|Para 1.47|Donations by private donors and donated<br>equipment.|
|Investment policy and<br>objectives including any<br>social investment policy<br>adopted|Para 1.46|N/A|
|A description of the principal<br>risks facing the charity|Para 1.46|At present funds are sufficient to achieve<br>the aims set, but more funding is needed to<br>be sought to continue to expand our work.<br>Ensuring the ongoing income is the most<br>important risk we manage.|
|Other||N/A|





## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:|||
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|Para 1.25|Constitution of the Association for the<br>Global Advancement of ENT Surgery and<br>Head and Neck Cancer Research (AGA-<br>ENT), a Charitable Incorporated<br>Organisation with voting members other<br>than its charity trustees<br>Date of constitution (last amended):<br>21/01/2016 (AGA-ENT Charity Governing<br>document - version 1.1 - 21/1/2016)|
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25|Charitable Incorporated Organisation|
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25|The current trustees volunteered to take on<br>these roles with the support of all founding<br>members and fulfil these roles in line with<br>the duties outlined in the AGA-ENT Charity<br>Governing document - version 1.1 -<br>21/1/2016|



## **Additional information (optional)** 

|**Additional information (optional)**|**Additional information (optional)**||
|---|---|---|
|You may choose to include further statements||where relevant about:|
|Policies and procedures<br>adopted for the induction<br>and training of trustees|Para 1.51|All duties outlined in the AGA-ENT Charity<br>Governing document - version 1.1 -<br>21/1/2016 and discussed during regular<br>Trustees’ meetings.|
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51|Charitable Incorporated Organisation with<br>voting members other than its charity<br>trustees|
|Relationship with any<br>related parties|Para 1.51|Collaborators and partners globally who<br>help to achieve the outlined objectives,<br>usually within the network of Founding<br>Members.|
|Other||N/A|



## **Reference and Administrative details** 

Charity name Association for the Global Advancement of ENT Surgery and - Head and Neck Cancer Research (AGA ENT) Other name the charity uses AGA-ENT Registered charity number 1165453 



|Charity’s principal address|Association for the Global Advancement of ENT Surgery and<br>Head and Neck Cancer Research (AGA-ENT), Health<br>Foundry, Canterbury House, 1 Royal Street, London, SE1<br>7LL|
|---|---|
|||





## **Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year**|**Name of person (or body) entitled**<br>**to appoint trustee (if any)**|
|---|---|---|---|---|
||Paul O’Flynn||5/2/2016 – current date|Membershipbody|
||Matt Lechner||5/2/2016 – current date|Membershipbody|
||Valerie J. Lund||5/2/2016 – current date|Membershipbody|
||Francis M. Vaz||5/2/2016 – current date|Membershipbody|
||Tim Tang||5/2/2016 - 4/6/2017|Membershipbody|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||



## – Corporate trustees names of the directors at the date the report was approved 

**Director name** N/A 

Name of trustees holding title to property belonging to the charity 

|**Trustee name**|**Dates acted if not for whole year**||
|---|---|---|
|N/A|||
||||
||||
||||
||||
||||





## **Funds held as custodian trustees on behalf of others** 

Description of the assets None held in this capacity 

Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|
|---|---|---|
|**Type of**<br>**adviser**<br>**Name**<br>**Address**|||
|N/A|||
||||
||||
||||
|**Name of chief executive or names of senior staff members (Optional information)**|||
|N/A|||



## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

The charity is too small still to employ personnel 

## **Other optional information** 

N/A 



## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

|**Signature(s)**<br>**Full name(s)**<br>**Position (eg Secretary,**<br>**Chair, etc)**<br>**Date**|||
|---|---|---|
||Matt Lechner||
||<br>Trustee||
||20/05/2021||
||20/05/2021||






**Association for the Global Advancement of ENT Surgery 1165453 and Head and Neck Cancer Research Receipts and payments accounts CC16a For the period** 25/07/2019 **To** 24/07/2020 **from** 

|**Section A Receipts and payments**|**Section A Receipts and payments**||||||
|---|---|---|---|---|---|---|
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**8,500**<br>**4,000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **12,500**<br>**-**<br>**-**<br> **-**<br>**12,500**<br>**421**<br>**634**<br>**4,000**<br>**5,000**<br>**258**<br>**132**<br>**960**<br>**137**<br>**-**<br>**41**<br>**-**<br>**-**<br> **11,584**<br>**-**<br>**-**<br> **-**<br>**11,584**<br>**916**<br>**-**<br>**3,212**<br>**4,128**|**Restricted funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total funds**<br>**to the nearest £**<br>**8,500**<br>**4,000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**12,500**<br>**-**<br>**-**<br>**-**<br>**12,500**<br>**421**<br>**634**<br>**4,000**<br>**5,000**<br>**258**<br>**132**<br>**960**<br>**137**<br>**-**<br>**41**<br>**-**<br>**-**<br>**11,584**<br>**-**<br>**-**<br>**-**<br>**11,584**<br> <br>**916**||**Last year**<br>**to the nearest £**|
|Donations|**8,500**|||||**6,583**|
|FellowshipFunding|**4,000**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**12,500**|||||**6,583**|
||||||||
|**A2 Asset and investment sales,**<br>**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|**_Sub total_**|**-**|||||**-**|
|**_Total receipts_**<br>**A3 Payments**|||||||
|||||||**6,583**|
||||||||
|Fundraisingcosts|**421**|||||**-**|
|Web hosting|**634**|||||**24**|
|FellowshipAwards|**4,000**|||||**4,000**|
|Research costs|**5,000**|||||**-**|
|Conference costs|**258**|||||**-**|
|Printing, postage and stationery|**132**|||||**-**|
|Office costs|**960**|||||**-**|
|Sundryexpenses|**137**|||||**292**|
||**-**|||||**-**|
|Bank charges|**41**|||||**80**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_ **|**11,584**|||||**4,396**|
||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**|||||||
||**-**||||||
||**-**||||||
|**_Sub total_ **|**-**|||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**|||||||
|||||||**4,396**|
||||||||
||**916**|**-**|**-**|<br>**916**||**2,187**|
||**-**|**-**|**-**|**-**||**-**|
||**3,212**|**-**|**-**|**3,212**||**1,025**|
||**4,128**|**-**|**-**|**4,128**||**3,212**|



1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B5 Liabilities**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B3 Investment assets**<br>**B2 Other monetary assets**<br>**B1 Cash funds**|Signature<br>**Details**<br>**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>**Details**<br>**Details**<br>Bank accounts<br>2|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**4,128**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**4,128**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>M Lechner|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
||||20/05/2021|
|||||



